CIK 0000812796 · Non-accelerated filer<br>Smaller reporting company
SOLIGENIX, INC.
Sign in to watch- Ticker
- SNGX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 411505029
- Phone
- 609-538-8200
- Business address
- 29 EMMONS DRIVE, SUITE B-10, PRINCETON, NJ, 08540
- Former names
- SOLIGENIX, INC., DOR BIOPHARMA INC, ENDOREX CORP, IMMUNOTHERAPEUTICS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-09-23 | ZELDIS JEROME B Director | Grant or award · Stock Option (Right to Buy) | +29,126 | 29,126 | ||
| 2021-09-23 | Parks Diane L. Director | Grant or award · Stock Option (Right to Buy) | +29,126 | 29,126 | ||
| 2021-05-14 | ZELDIS JEROME B Director | Purchase | +3,000 | $0.89 | $3K | 25,917 |
| 2021-05-14 | ZELDIS JEROME B Director | Sale | −3,000 | $0.90 | $3K | 22,917 |
| 2021-01-04 | SCHABER CHRISTOPHER J Chairman, CEO and President | Grant or award · Option (Right to Buy) | +60,000 | 60,000 | ||
| 2020-12-10 | Guarino Jonathan L. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2020-12-10 | Straube Richard CMO | Grant or award · Option (Right to Buy) | +40,000 | 40,000 | ||
| 2020-12-10 | SCHABER CHRISTOPHER J Chairman, CEO and President | Grant or award · Option (Right to Buy) | +60,000 | 60,000 | ||
| 2020-12-10 | Donini Oreola CSO | Grant or award · Option (Right to Buy) | +70,000 | 70,000 | ||
| 2020-09-16 | ZELDIS JEROME B Director | Grant or award · Stock Option (Right to Buy) | +15,228 | 15,228 | ||
| 2020-09-16 | LAPOINTE ANTHONY GREGG Director | Grant or award · Stock Option (Right to Buy) | +15,228 | 15,228 | ||
| 2020-09-16 | RUBIN ROBERT J. Director | Grant or award · Stock Option (Right to Buy) | +15,228 | 15,228 | ||
| 2020-09-16 | Parks Diane L. Director | Grant or award · Stock Option (Right to Buy) | +15,228 | 15,228 | ||
| 2020-06-18 | Parks Diane L. Director | Grant or award · Stock Option (Right to Buy) | +13,500 | 13,500 | ||
| 2020-01-02 | SCHABER CHRISTOPHER J Chairman, CEO and President | Grant or award · Option (Right to Buy) | +60,000 | 60,000 | ||
| 2019-12-12 | Straube Richard SVP and CMO | Grant or award · Option (Right to Buy) | +30,000 | 30,000 | ||
| 2019-12-12 | SCHABER CHRISTOPHER J Chairman, CEO and President | Grant or award · Option (Right to Buy) | +60,000 | 60,000 | ||
| 2019-12-12 | Guarino Jonathan L. Senior Vice President & CFO | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2019-12-12 | Donini Oreola SVP and CSO | Grant or award · Option (Right to Buy) | +60,000 | 60,000 | ||
| 2019-11-19 | ZELDIS JEROME B Director | Purchase | +2,000 | $0.93 | $2K | 22,917 |
Page 6 of 8 · 141 trades